Phase II Study of Vincristine Sulfate Liposome Injection (Marqibo) and Rituximab for Patients With Relapsed and Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma in Need of Palliative Therapy

Kaplan, Lawrence D.; Deitcher, Steven R.; Silverman, Jeffrey A.; Morgan, Gareth J.

doi:10.1016/j.clml.2013.09.009

Cited by 33 publications

(27 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[18, 29, 34-38] The alkaloid can bind to tubulin, causing microtubule depolymerization, metaphase arrest, and apoptosis in cells undergoing mitosis. [18, 34, 35, 39, 40] Vincristine have been used for many years by clinics to treat malignancies including philadelphia chromosome-negative acute lyphoblastic leukemia,[22, 41] B-cell lymphoma,[42, 43] metastatic melanoma,[38] estrogen-receptor-negative breast cancer,[40] glioma,[44, 45] colorectal cancer,[21] non-Hodgkin’s lymphoma,[39, 46] Hodgkin’s lymphoma, neuroblastoma, rhabdomyosarcoma, multiple myeloma, and Wilms’ tumor. [2] However, its applications are restricted by severely neurotoxic side effects.…”

Section: Vincristinementioning

confidence: 99%

“…[54-58] Because they resemble cell membranes with non-immunogenicity, highly biocompatibility, and safe, liposomes have been widely used in drug delivery systems. [41] Liposomal vincristine (Marqibo®), which has been approved by the US Food and Drug Administration (FDA), has been widely applied in many cancers therapies [22, 39-41, 43, 45, 46]. Table 1 lists the advantages of drug delivery systems, including half-life, uptake, concentration enhancement, and sustained-release characteristics.…”

Section: Vincristinementioning

confidence: 99%

See 1 more Smart Citation

Drug Delivery Systems and Combination Therapy by Using Vinca Alkaloids

Lee¹,

Huang²,

Yang³

et al. 2015

CTMC

View full text Add to dashboard Cite

Developing new methods for chemotherapy drug delivery has become a topic of great concern. Vinca alkaloids are among the most widely used chemotherapy reagents for tumor therapy; however, their side effects are particularly problematic for many medical doctors. To reduce the toxicity and enhance the therapeutic efficiency of vinca alkaloids, many researchers have developed strategies such as using liposome-entrapped drugs, chemical- or peptide-modified drugs, polymeric packaging drugs, and chemotherapy drug combinations. This review mainly focuses on the development of a vinca alkaloid drug delivery system and the combination therapy. Five vinca alkaloids (eg, vincristine, vinblastine, vinorelbine, vindesine, and vinflunine) are reviewed.

show abstract

Section: Vincristinementioning

confidence: 99%

Section: Vincristinementioning

confidence: 99%

Drug Delivery Systems and Combination Therapy by Using Vinca Alkaloids

Lee¹,

Huang²,

Yang³

et al. 2015

CTMC

View full text Add to dashboard Cite

show abstract

“…The efficacy of palliative therapy of vincristine-loaded SM/Chol liposomes plus rituximab for patients with advanced, relapsed, and refractory diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) was confirmed by Kaplan et al (2014). The dose of vincristine was 2.0 mg/m 2 every two weeks, and the dose of rituximab was 375 mg/m 2 every week.…”

Section: Combination Therapymentioning

confidence: 99%

Are PEGylated liposomes better than conventional liposomes? A special case for vincristine

Wang

Song

et al. 2015

Drug Delivery

View full text Add to dashboard Cite

Cancer poses a significant threat to human health worldwide, and many therapies have been used for its palliative and curative treatments. Vincristine has been extensively used in chemotherapy. However, there are two major challenges concerning its applications in various tumors: (1) Vincristine's antitumor mechanism is cell-cycle-specific, and the duration of its exposure to tumor cells can significantly affect its antitumor activity and (2) Vincristine is widely bio-distributed and can be rapidly eliminated. One solution to these challenges is the encapsulation of vincristine into liposomes. Vincristine can be loaded into conventional liposomes, but it quickly leak out owing to its high membrane permeability. Numerous approaches have been attempted to overcome this problem. Vincristine has been loaded into PEGylated liposomes to prolong circulation time and improve tumor accumulation. These liposomes indeed prolong circulation time, but the payout characteristic of vincristine is severer, resulting in a compromised outcome rather than a better efficacy compared to conventional sphingomyelin (SM)/cholesterol (Chol) liposomes. In 2012, the USA Food and Drug Administration (FDA) approved SM/Chol liposomal vincristine (Marqibo Õ ) for commercial use. In this review, we mainly focus on the drug's rapid leakage problem and the potentially relevant solutions that can be applied during the development of liposomal vincristine and the reason for conventional liposomal vincristine rather than PEGylated liposomes has access to the market.

show abstract

“…clinical efficacy of these treatments are publically available, (19). Due to the presence of PEG, Doxil® can avoid reticuloendothelial system (RES) and is characterized by longer EHL, larger 6 AUC and lower clearance than with Myocet (table 1) (20). However, hand-foot syndrome cannot be avoided, (21).…”

Section: I1 Lipid Based Nanoformulationmentioning

confidence: 99%

“…When it was administered intravenously at a dose of 2.5 mg/m 2 on 13 patients, it resulted in a clearance of 345 mL/h, higher than that of 189 mL/h observed with free vincristine, a higher MTD, a superior antitumor activity, a larger amount of vincristine delivered to tumour tissues compared with free vincristine (4,5). Marqibo was also tested clinically for treatment of large B-cell lymphoma (6) and non-Hodgkin Lymphoma (7), (table 2).…”

Section: I1 Lipid Based Nanoformulationmentioning

confidence: 99%